ArticleActa diabetologica2025
The association of peripheral blood METTL3 mRNA expression levels with prediabetes and type 2 diabetes mellitus: the Henan rural cohort study.
Article in Acta diabetologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimWe aimed to investigate the association of peripheral blood METTL3 (Methyltransferase Like 3) mRNA expression levels with impaired fasting glucose (IFG) and type 2 diabetes mellitus (T2DM). MATERIALS AND
methodsA case-control study including 1501 participants from the Henan Rural Cohort study was performed. Peripheral blood METTL3 mRNA expression levels were quantified by qRT-PCR. Binary logistic regression was used to generate odds ratio (OR) and 95% confidence intervals (CI) for the risk of IFG and T2DM. Restricted cubic spline was used to generate the dose-response relationship between METTL3 mRNA expression levels and IFG and T2DM.
resultsMETTL3 mRNA expression levels were downregulated in T2DM compared with normal glucose tolerance (NGT) (4.03 ± 1.09 vs. 3.96 ± 0.93). After adjusting covariates, the risk of developing IFG in METTL3 mRNA high expression levels group was 30% higher than that in the low expression levels group (OR = 1.30,95%CI:1.02,1.65). Conversely, METTL3 mRNA expression levels were negatively correlated with T2DM(OR = 0.83,95%CI:0.72,0.96) compared to the NGT group. METTL3 mRNA expression levels showed a non-linear correlation with both IFG and T2DM.
conclusionMETTL3 mRNA expression levels exhibited opposing effects on IFG and T2DM. Elevated METTL3 mRNA levels were positively associated with IFG risk but inversely associated with T2DM risk.
Indexed as
Identifiers
40540211What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.